[New strategy for targeting influenza virus replication].
Dias
Alexandre
A
Bouvier
Denis
D
Cusack
Stephen
S
Ruigrok
Rob W H
RW
Crépin
Thibaut
T
D000613:Aminobutyrates / Q000494:pharmacology*; D000998:Antiviral Agents / Q000494:pharmacology*; D016503:Drug Delivery Systems; D004353:Drug Evaluation, Preclinical; D008954:Models, Biological; D008958:Models, Molecular; D009975:Orthomyxoviridae / Q000187:drug effects* / Q000502:physiology; D010654:Phenylbutyrates; D011487:Protein Conformation; D017434:Protein Structure, Tertiary; D012315:RNA Caps / Q000378:metabolism; D012367:RNA, Viral / Q000235:genetics / Q000378:metabolism; D012324:RNA-Dependent RNA Polymerase / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000502:physiology; D014764:Viral Proteins / Q000037:antagonists & inhibitors* / Q000737:chemistry / Q000502:physiology; D014779:Virus Replication / Q000187:drug effects*
C515357:2,4-dioxo-4-phenylbutanoic acid; D000613:Aminobutyrates; D000998:Antiviral Agents; C061290:PA protein, influenza viruses; C502893:PB2 protein, influenza virus; D010654:Phenylbutyrates; D012315:RNA Caps; D012367:RNA, Viral; D014764:Viral Proteins; C077346:influenza virus polymerase basic protein 1; D012324:RNA-Dependent RNA Polymerase